Literature DB >> 1636228

Natural history of superficial bladder cancer. Prognostic features and long-term disease course.

N M Heney1.   

Abstract

Superficial bladder cancer or, more accurately, stages Ta, T1, and Tis encompass a spectrum that ranges from innocuous to life-threatening lesions. There is growing evidence that Ta grade 1 tumors rarely become invasive; although when there is associated carcinoma in situ or severe dysplasia, the risk of invasiveness increases. Carcinoma in situ is treacherous, with unpredictable behavior. Predictors of recurrence and progression are beginning to be identified for the various superficial tumors.

Entities:  

Mesh:

Year:  1992        PMID: 1636228

Source DB:  PubMed          Journal:  Urol Clin North Am        ISSN: 0094-0143            Impact factor:   2.241


  51 in total

Review 1.  Current problems and needs in the treatment of pT1 G3 bladder carcinoma.

Authors:  Francisco Jose Martínez Portillo; Peter Alken
Journal:  Int Urol Nephrol       Date:  2002       Impact factor: 2.370

2.  Canadian guidelines for treatment of non-muscle invasive bladder cancer: a focus on intravesical therapy.

Authors:  Wassim Kassouf; Ashish M Kamat; Alexander Zlotta; Bernard H Bochner; Ronald Moore; Alan So; Jonathan Izawa; Ricardo A Rendon; Louis Lacombe; Armen G Aprikian
Journal:  Can Urol Assoc J       Date:  2010-06       Impact factor: 1.862

3.  CUA guidelines on the management of non-muscle invasive bladder cancer.

Authors:  Wassim Kassouf; Samer L Traboulsi; Girish S Kulkarni; Rodney H Breau; Alexandre Zlotta; Andrew Fairey; Alan So; Louis Lacombe; Ricardo Rendon; Armen G Aprikian; D Robert Siemens; Jonathan I Izawa; Peter Black
Journal:  Can Urol Assoc J       Date:  2015-10-13       Impact factor: 1.862

4.  Selecting patients for immediate cystectomy.

Authors:  Shahrokh F Shariat
Journal:  Rev Urol       Date:  2007

5.  A randomized controlled trial of celecoxib to prevent recurrence of nonmuscle-invasive bladder cancer.

Authors:  Anita L Sabichi; J Jack Lee; H Barton Grossman; Suyu Liu; Ellen Richmond; Bogdan A Czerniak; Jorge De la Cerda; Craig Eagle; Jaye L Viner; J Lynn Palmer; Seth P Lerner
Journal:  Cancer Prev Res (Phila)       Date:  2011-08-31

6.  Bioinformatics analysis of the target gene of fibroblast growth factor receptor 3 in bladder cancer and associated molecular mechanisms.

Authors:  Xing Ai; Zhuo-Min Jia; Juan Wang; Gui-Ping DI; X U Zhang; Fengling Sun; Tong Zang; Xiumei Liao
Journal:  Oncol Lett       Date:  2015-05-19       Impact factor: 2.967

7.  Impact of concomitant carcinoma in situ on upstaging and outcome following radical cystectomy for bladder cancer.

Authors:  Faysal A Yafi; Armen G Aprikian; Joseph L Chin; Yves Fradet; Jonathan Izawa; Eric Estey; Adrian Fairey; Ricardo Rendon; Ilias Cagiannos; Louis Lacombe; Jean-Baptiste Lattouf; Fred Saad; David Bell; Darrel Drachenberg; Wassim Kassouf
Journal:  World J Urol       Date:  2013-11-10       Impact factor: 4.226

8.  Squamous cell carcinoma of the bladder: poor response to neoadjuvant chemotherapy.

Authors:  Aaron Dotson; Allison May; Facundo Davaro; Syed Johar Raza; Sameer Siddiqui; Zachary Hamilton
Journal:  Int J Clin Oncol       Date:  2019-02-01       Impact factor: 3.402

9.  Evaluation of cellular fibronectin plasma levels as a useful staging tool in different stages of transitional cell carcinoma of the bladder and renal cell carcinoma.

Authors:  A Hegele; R Hofmann; B Kosche; J Kropf
Journal:  Biomark Insights       Date:  2007-02-07

10.  Molecular markers in transitional cell carcinoma of the bladder: New insights into mechanisms and prognosis.

Authors:  Behfar Ehdaie; Dan Theodorescu
Journal:  Indian J Urol       Date:  2008-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.